A share price of Deciphera Pharmaceuticals Inc [DCPH] is currently trading at $16.91, up 2.86%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The DCPH shares have gain 8.75% over the last week, with a monthly amount glided 18.58%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 27, February 2024, Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences. In a post published today on Yahoo Finance, Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences:.
From an analyst’s perspective:
Previously, Piper Sandler upgraded its rating to Overweight on October 30, 2023, and kept the price target unchanged to $23. On August 10, 2023, upgrade upgraded it’s rating to Buy and revised its price target to $20 on the stock. Guggenheim upgraded its rating to a Buy but stick to its price target of $22 on January 04, 2023. Cowen initiated its recommendation with a Outperform and recommended $25 as its price target on August 29, 2022. JMP Securities upgraded its rating to Mkt Outperform for this stock on August 05, 2022, but kept the price target unchanged to $23. In a note dated February 28, 2022, Barclays downgraded an Underweight rating on this stock and revised its target price from $11 to $6.
Deciphera Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $9.90 and $17.69. Currently, Wall Street analysts expect the stock to reach $21.33 within the next 12 months. Deciphera Pharmaceuticals Inc [NASDAQ: DCPH] shares were valued at $16.91 at the most recent close of the market. An investor can expect a potential return of 26.14% based on the average DCPH price forecast.
Analyzing the DCPH fundamentals
Trailing Twelve Months sales for Deciphera Pharmaceuticals Inc [NASDAQ:DCPH] were 163.36M which represents 32.88% growth. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.38 points at the first support level, and at 15.85 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.19, and for the 2nd resistance point, it is at 17.47.
Deciphera Pharmaceuticals Inc [DCPH] reported earnings per share of -$0.54 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.58/share, meaning a difference of $0.04 and a surprise factor of 6.90%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.58 per share as compared to estimates of -$0.61 per share, a difference of $0.03 representing a surprise of 4.90%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Deciphera Pharmaceuticals Inc [NASDAQ:DCPH] is 3.80. In addition, the Quick Ratio stands at 3.59 and the Cash Ratio stands at 0.05. Considering the valuation of this stock, the price to sales ratio is 8.36, the price to book ratio is 3.88.
Transactions by insiders
Recent insider trading involved Kelly Thomas Patrick, Chief Financial Officer, that happened on Feb 16 when 3010.0 shares were sold. EVP & Chief Medical Officer, Sherman Matthew L completed a deal on Feb 16 to sell 2615.0 shares. Meanwhile, Chief Commercial Officer Martin Daniel C. sold 2267.0 shares on Feb 16.
